利培酮治疗抑郁症与神经症患者躯体化症状临床研究_0.docVIP

利培酮治疗抑郁症与神经症患者躯体化症状临床研究 【关键词】 利培酮；躯体化症状；抑郁症；神经症；联合用药 　　【摘要】 目的 探讨利培酮 治疗 抑郁症与神经症患者躯体化症状的临床疗效。 方法 将37例有明显躯体化症状的抑郁症和神经症患者随机分为 研究 组和对照组，两组均进行抗抑郁及抗焦虑治疗的同时，研究组联合小剂量利培酮治疗，疗程6 w。治疗前及治疗2 w、4 w、6 w末采用症状自评量表进行临床疗效评定与 分析 。 结果 研究组治疗4 w、6 w末躯体化因子评分较治疗前均有显著下降，与对照组同期评分比较差异有显著或极显著性（P0.05或0.01）。 结论 利培酮联合抗抑郁及抗焦虑药物治疗躯体化症状疗效较好。 　　【关键词】 利培酮；躯体化症状；抑郁症；神经症；联合用药 　　Clinical studies of risperdone in somatization symptoms of patients with depression and neurosis 　　Zhang Shufang, Ma Chuangsheng 　　( The Eighth Peoples′ Hospital of Zhengzhou, 450006, Henan, China) 　　【Abstract】 Objective To explore the curative effects of risperdone in the treatment of somatization symptoms of patients with depression and neurosis. Methods 37 patients with depression and neurosis who had obvious somatization symptoms were randomly divided into research group(n=19) and control group(n=18), both 2 groups recEIved antidepressants and antianxietic, meanwhile the research group combined with low dosed of risperdone for 6 weeks. Curative effects were assessed with the Symptom Checklist 90(SCL90) before treatment and at the ends of the 2nd, 4th and 6th week of treatment. Results At the ends of the 4th and 6th week, somatization factor score decreased significantly in the research group compared with pretreatment and had significant and very difference from the control group(P0.05 or 0.01). Conclusion Risperdone combined with antidepressants and antianxietic has better effectiveness in somatization symptoms. 　　【Keywords】 Risperdone; somatization symptom; depression; neurosis; combining medication 　　躯体化症状是精神科常见的以躯体不适感为主的综合症，可涉及各个系统，以疼痛感、麻木感、凉热感、气胀感等为主要表现，但临床检查无阳性体征。常见于抑郁症、神经症患者，一般治疗效果较差。为此，作者在抗抑郁及抗焦虑治疗的基础上联合小剂量利培酮进行了对照研究，取得了较满意的疗效，现报告如下。 　　1 对象与方法 　　1.1 对象 选取2004年8月～2005年10月在我院住院的神经症和抑郁症患者为研究对象。入组标准：（1）符合《 中国 精神障碍分类与诊断标准》第3版(CCMD3)抑郁症或神经症诊断标准。（2）入院前2 w未服用抗精神病药物；（3）症状自评量表（SCL90）［1］评分躯体化因子≥2.5分。（4）排除严重躯体疾病、脑器质性疾病、药物滥用、妊娠、哺乳期妇女及药物过敏者等。共入组37例，其中抑郁症21例，躯体形式障碍11例，焦虑症3例，恐怖症1例，强迫症1例。男9例，女28例；年龄22 a～72 a，病程2 mo～26 a。将入组病例随